By contrast, most of the T2D patients in the RYGB group were treated with oral hypoglycemic agents, glucagon-like peptide-1 (GLP-1) receptor agonists and/or insulin (Table 1). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.